openPR Logo
Press release

Constipation Treatment Market to Reach an Overall Valuation of US$22.93 Billion by 2025

09-13-2017 02:08 PM CET | Health & Medicine

Press release from: TMR - Research Reports

Constipation Treatment Market to Reach an Overall Valuation

As per the evaluations of the TMR report, the global constipation treatment market was worth US$12.58 bn in 2016. During the forecast period of 2017 to 2025, the TMR report projects the global constipation treatment market to exhibit a healthy CAGR of 7.1%, estimating it to reach an overall valuation of US$22.93 bn by 2025.

Based on therapeutic option, the global constipation treatment market earns maximum demand for laxatives segment, which is further bifurcated into bulk forming agents, osmotic laxatives, and stimulant laxatives. The laxative segment is anticipated to experience incrementing demand at CAGR 7.0% during the forecast period, owing to low cost and wide availability. On the basis of disease type, the global market for constipation treatment has most prominent demand for opioid induced constipation (OIC), whereas hospitals continue to be the best distribution channel category. Geographically, although the developed region of North America is currently most lucrative, Asia Pacific has been projected as quickly emerge as highly profitable regional market during the forecast period.

Request to download and view full ToC - http://www.transparencymarketresearch.com/report-toc/16442

Emerging Economies Opening New Opportunities for Market

Constipation is a common phenomenon, experienced by almost every individual at some point of their lifetime, if not frequently, and is evident in 8% to 32.5% of population across the globe. The choice of medicines to treat the constipation depends upon the type of constipation. Increasing geriatric population and changing dietary habits in developed as well developing markets is expected to increase the incidences of functional constipation across the globe in the near future. It is estimated that more than half of people above 50 years of age are prone to have chronic constipation. Moreover, leading industry players are investing on development of novel specialty constipation treatment drugs, which is anticipated to propel the growth of constipation treatment market. Surge in opioids consumption for relieving chronic pain is another favorable factors for the global constipation treatment market. There is high prevalence of irritable bowel syndrome in emerging markets such as Asia Pacific and Latin America. Around 35% IBS patients are likely to be affected with constipation (IBS-C). This high prevalence of IBS-C, OIC and chronic constipation is estimated to drive expansion of constipation treatment market across the globe.

Request to view Sample Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=16442

Over-reliance on OTC Restraining Market Growth

The TMR report notes that despite a number of drivers and vast opportunities, the global constipation treatment market is hindered by the continuous reliance of a majority on over-the-counter (OTC) drugs, as well as on generic laxatives. In addition to that, the specialty constipation drugs have not reached every corner of the world due to the lack of proper healthcare infrastructure in various emerging economies. Though this may currently obstruct the market, the leading players will gain new opportunities if they strategically invest on reaching these unmet demands.

A freshly-compiled intelligence study by Transparency Market Research (TMR) has noted that a vast number of players are participating in the global constipation treatment market, which has been a prevalent disorder among the masses for several decades. With resilient research and development, latest drugs and treatment procedures have enabled caregivers to bring relief to the patients, and consequently opened widespread opportunities for the companies venturing in the constipation treatment market. The report identifies and profiles a number of key players who hold position of strength in the global constipation treatment market, including Bayer AG, Sanofi, Takeda Pharmaceuticals Company Limited, Sucampo Pharmaceuticals, Inc., Ironwood Pharmaceuticals, Inc., Synergy Pharmaceuticals, Inc., Valeant Pharmaceuticals International, Inc., AstraZeneca, Abbott Laboratories, Valeant Pharmaceuticals International, Inc., Daewoong Pharmaceuticals Co. Ltd., Cosmo Pharmaceuticals NV, Prestige Brands Holdings, Inc., Janssen Pharmaceutical Company, Shionogi & Co., Ltd., Renexxion, LLC., and Albireo Pharma, Inc.

Buy Global Constipation Treatment Market Report for US$ 5795 @ http://www.transparencymarketresearch.com/checkout.php?rep_id=16442

About TMR

Transparency Market Research (TMR) is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Constipation Treatment Market to Reach an Overall Valuation of US$22.93 Billion by 2025 here

News-ID: 714623 • Views:

More Releases from TMR - Research Reports

Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2024
Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2 …
According to the research report, the global pulmonary drugs market is expected to be worth US$ 28,082.1 mn by the end of 2024 as compared to US$ 48,039.7 mn in 2015. Analysts calculate that the global market will plummet at a CAGR of -6.3% during the forecast period of 2016 and 2024. The market will thrive as the demand for combination drugs is anticipated to remain on the rise during
North America Ventricular Assist Device Market is rising to a valuation of US$ 1.07 Billion by 2024
North America Ventricular Assist Device Market is rising to a valuation of US$ 1 …
According to TMR, the opportunity in the North America market for VADs, which stood at US$0.4 bn in 2015, is likely to expand at a healthy CAGR of 9.20% between 2016 and 2024 and increase to US$1.07 bn by the end of the forecast period. The destination therapy (DT) segment has been reporting a greater application of VADs than the other two indication segments. It is expected to remain the
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million by 2024
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million b …
Transparency Market Research notes that innovation and expansion into emerging regions have served these companies well in strengthening their hold in the dental membrane and bone graft substitutes market. For instance, Switzerland-based Geistlich Pharma AG - a global manufacturer and supplier of dental products and devices - expanded its operations in Sydney, Australia and New Delhi, India in 2016. The global dental membrane and bone graft substitutes market is expected to
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
The global human vaccines market was valued at US$28.3 bn in 2015 and is estimated to reach US$72.5 bn by 2024, registering an 11.2% CAGR during the forecast period. By age group, pediatric vaccines accounted for a 57.5% share in the global human vaccines market in 2015. Adult vaccines, on the other hand, are expected to expand at a 13.2% CAGR from 2016 to 2024. Based on product, the pneumococcal segment

All 5 Releases


More Releases for Pharma

Miglitol Market Size, Share and Forecast By Key Players-Weiao Pharma, Zhejiang M …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Miglitol market is anticipated to grow at a compound annual growth rate (CAGR) of 11.49% between 2024 and 2031. The market is expected to grow to USD 22.32 Billion by 2024. The valuation is expected to reach USD 47.79 Billion by 2031. The Miglitol market is experiencing significant growth due to the rising prevalence of diabetes and the increasing awareness of the
Dacarbazine Market Size, Share and Forecast By Key Players-Lingnan Pharma, Ruiyi …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Dacarbazine market is anticipated to grow at a compound annual growth rate (CAGR) of 14.63% between 2024 and 2031. The market is expected to grow to USD 25.32 Billion by 2024. The valuation is expected to reach USD 65.84 Billion by 2031. The Dacarbazine market is projected to witness significant growth in the coming years, driven by increasing
Dacarbazine Market Size, Share and Forecast By Key Players-Lingnan Pharma, Ruiyi …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Dacarbazine market is anticipated to grow at a compound annual growth rate (CAGR) of 14.63% between 2024 and 2031. The market is expected to grow to USD 25.32 Billion by 2024. The valuation is expected to reach USD 65.84 Billion by 2031. The dacarbazine market is experiencing steady growth, driven by the rising incidence of cancer globally. As
Epilepsy Pipeline Assessment 2024: Therapies, Clinical Trials, and Market Insigh …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Epilepsy pipeline constitutes 75+ key companies continuously working towards developing 90+ Epilepsy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The Epilepsy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the
Global Indomethacin Market Seeking Excellent Growth by 2028 | Ratiopharm, Merck, …
"IBI has published a report entitled Global Indomethacin Market Research Report which provides comprehensive data on emerging trends, market drivers, growth opportunities, and barriers that could change the dynamics of the industry market. It provides an in-depth analysis of market segments which includes the product, application, and competitor analysis. Click Here To Order A Sample Copy Of Indomethacin Global Market Report : https://www.infinitybusinessinsights.com/request_sample.php?id=380382 The Indomethacin Global Market Research Report provides close monitoring
Roxatidine Market 2020: Top Companies Analysis To Grow Healthcare Business by 20 …
Business Industry Reports Research has recently announced a report on Global Roxatidine Market based on the Category Industry. The Roxatidine Market report emphasizes various key aspects, which include growth drivers, restraints, opportunities and recent market trends for the forecast period 2020-2024. Global Roxatidine Market overview: Business Industry Reports Analyst covers the Major Players data, including: shipment, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the